Table 2.
Summary of the investigated outcomes after kidney transplantation with and withour pre-transplant DSA, and the induction therapy applied on the DSA patients.
| Parameter | DBD total patients (n=1282) | DSA (n=271) | No DSA (n=1011) | p value (DSA vs. No DSA) |
|---|---|---|---|---|
| ABMR | 9.3% | 30.6% | 3.6% | <0.0001 |
| TCMR | 18.6% | 15.9% | 19.4% | 0.006 |
| Graft loss | 13.8% | 17.7% | 12.8% | <0.0001 |
| Mean eGFR (ml/min/1.73m2) |
50.76 | 49.82 | 51.69 | 0.967 |
| Mean eGFR slope (ml/min/1.73m2/year) |
-0.84 | -1.27 | -0.42 | 0.013 |
| Mean total eGFR slope (ml/min/1.73m2/year) |
-1.25 | -1.65 | -0.85 | 0.024 |
| Induction therapy | ||||
| ATG/Thymo | 24.5% | 64.9% | 13.6% | <0.0001 |
| Basiliximab | 73.6% | 34.7% | 84.1% | <0.0001 |
| No induction | 1.9% | 0.4% | 2.3% | <0.0001 |
| Parameter | LD total patients (n=803) | DSA (n=117) | No DSA (n=686) | p value (DSA vs. No DSA) |
| ABMR | 6.6% | 11.9% | 4.7% | <0.0001 |
| TCMR | 16.1% | 18.8% | 15.6% | 0.092 |
| Graft loss | 6.7% | 11.1% | 6.0% | <0.0001 |
| Mean eGFR (ml/min/1.73m2) |
52.53 | 50.10 | 54.95 | 0.638 |
| Mean eGFR slope (ml/min/1.73m2/year) |
-0.36 | -0.28 | -0.44 | 0.793 |
| Mean total eGFR slope (ml/min/1.73m2/year) |
-0.71 | -0.72 | -0.70 | 0.682 |
| Induction therapy | ||||
| ATG/Thymo | 17.6% | 67.5% | 9.0% | <0.0001 |
| Basiliximab | 78.3% | 32.5% | 86.2% | <0.0001 |
| No induction | 4.1% | 0.0% | 4.8% | <0.0001 |
| Parameter | DCD total patients (n=130) | DSA (n=23) | No DSA (n=107) | p value (DSA vs. No DSA) |
| ABMR | 1.5% | 8.7% | 0.0% | <0.0001 |
| TCMR | 8.5% | 4.3% | 9.3% | 0.106 |
| Graft loss | 7.7% | 17.4% | 5.6% | <0.0001 |
| Mean eGFR (ml/min/1.73m2) |
54.67 | 58.86 | 50.49 | 0.820 |
| Mean eGFR slope (ml/min/1.73m2/year) |
-0.32 | -0.85 | 0.21 | 0.266 |
| Mean total eGFR slope (ml/min/1.73m2/year) |
-0.86 | -1.61 | -0.12 | 0.408 |
| Induction therapy | ||||
| ATG/Thymo | 72.3% | 87.0% | 69.2% | <0.0001 |
| Basiliximab | 26.9% | 13.0% | 29.9% | <0.0001 |
| No induction | 0.8% | 0.0% | 0.9% | 0.352 |